Contribute Try STAT+ Today

Twenty-two patients with inherited blood disorders were free of severe pain and the need for transfusions months after receiving an experimental genome-editing medicine, more evidence the CRISPR-based treatment could be a functional cure.

The therapy, jointly developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is designed to treat sickle cell disease and beta-thalassemia by boosting the body’s production of hemoglobin. According to data from two clinical trials presented at the European Hematology Association annual meeting Friday, all patients in both studies have been free from symptoms of the diseases since their treatment and have not needed blood transfusions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment